1-4 of 4
Peter Feng Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Outcomes of Medicare Fee-for-Service Beneficiaries Meeting the Eligibility Criteria for the DREAMM-7 and DREAMM-8 Clinical Trials

Simon McNamara, Natalie Boytsov, Peter Feng Wang, Maya Hanna, Anjali Franco, Benjamin Lewing, Barth Kelly, Joseph Tkacz
Journal: Blood
Blood (2023) 142 (Supplement 1): 1965.
https://doi.org/10.1182/blood-2023-181668
Published: 2023
Journal Articles

Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study

Joshua Richter, Peter Feng Wang, Alexa Molinari, Boris Gorsh, Natalie Boytsov, Suzanne Landi, Sue Perera, Prani Paka, Teresa Palumbo, Mei Sheng Duh, Christopher Yee, Anamika Khanal, Sonia Gupta, Ajai Chari
Journal: Blood
Blood (2022) 140 (Supplement 1): 4338–4340.
https://doi.org/10.1182/blood-2022-164918
Published: 2022
Journal Articles

Efficacy and Safety of Third-Line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review

Maya Hanna, Justyna Chorazy, Ike Iheanacho, Boris Gorsh, Peter Feng Wang, Prani Paka, Sue Perera
Journal: Blood
Blood (2022) 140 (Supplement 1): 12559–12560.
https://doi.org/10.1182/blood-2022-167521
Published: 2022
Journal Articles

Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies

Natalie Boytsov, Boris Gorsh, Seth Anderson, Peter Feng Wang, Sue Perera, Meg Franklin
Journal: Blood
Blood (2022) 140 (Supplement 1): 12554–12555.
https://doi.org/10.1182/blood-2022-167184
Published: 2022